aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
InterVenn Biosciences, founded in South San Francisco, California, is a pioneering life science company focused on unlocking the value of glycoproteomics for transformational healthcare solutions. Their core mission is to leverage glycosylated proteins, which drive protein function, to develop advanced medical insights and treatments. InterVenn's GlycoVision™ platform utilizes AI to enhance the speed, scope, and scale of glycoproteomics, enabling breakthroughs in biomarker discovery, disease detection and progression, therapeutic response, and monitoring.
Notable affiliated individuals include founders and key scientific advisors who are leaders in biotechnology and AI. The company has attracted significant investments from prominent venture capital firms, underscoring its potential impact. Key achievements include the development of their proprietary GlycoVision™ platform and its application in precision medicine. InterVenn Biosciences is poised to revolutionize healthcare by providing unprecedented insights into human biology through high-resolution glycoproteomics.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Healthcare, Biotech
Technology
Analytics, AI
Tags
Healthtech
Model Types
Platform, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was InterVenn Biosciences founded?
InterVenn Biosciences was founded in 2017.
Where is InterVenn Biosciences’s headquarters located?
InterVenn Biosciences’s headquarters is located in Redwood City, CA, US.
When was InterVenn Biosciences’s last funding round?
InterVenn Biosciences’s most recent funding round was for $201M (USD) in August 2021.
How many employees does InterVenn Biosciences have?
InterVenn Biosciences has 155 employees as of Feb 5, 2024.
How much has InterVenn Biosciences raised to-date?
As of July 05, 2023, InterVenn Biosciences has raised a total of $278.1M (USD) since Aug 2, 2021.
Add Comparison
Total Raised to Date
$278.1M
USD
Last Update Aug 2, 2021
Last Deal Details
$201M
USD
Aug 2, 2021
Series C
Total Employees Over Time
155
As of Feb 2024
InterVenn Biosciences Address
Redwood City,
California
94065
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts